ArticleEBioMedicine2026
Serum inflammatory proteomic signatures define chronic inflammatory demyelinating polyneuropathy and inform on disease activity.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated neuropathy with heterogeneous presentation and variable treatment response. Blood-based biomarkers remain lacking, and interpretation is confounded by widespread immunoglobulin (IG) therapy. The primary aim was to identify serum inflammatory proteomic signatures associated with CIDP; exploratory aims included associations with disease activity, phenotype, and treatment response.
methodsIn this case-control study, 92 proteins were quantified using multiplex proximity extension assay and ELISA in 358 sera samples from patients with CIDP, multiple sclerosis (MS), and IG-treated myasthenia gravis (MG) as well as age- and sex- matched healthy controls (HC). Logistic regression with Bonferroni correction, principal component analysis, and correlation analyses were applied to identify differential expression across diagnoses and CIDP subgroups.
findingsSeven proteins, TNFSF14, CD40, SIRT2, CCL3, IL8, TGFα, and uPA, consistently distinguished CIDP from HC, MS, and IG-treated MG, representing disease-specific signatures independent of IG exposure. Six additional proteins (STAMBP, CASP-8, EN-RAGE, OSM, HGF, and CXCL6) were IG-responsive. CXCL9, CDCP1, and CCL20 correlated with muscle weakness, while calprotectin and neurofilament light chain reflected broader inflammatory and axonal injury signatures. Patients with unstable active disease exhibited higher CCL4, IL-8, CCL3, FGF-21, and IL-17A. IL-8, EN-RAGE, and CASP-8 predicted clinical improvement, and IL-5 tracked longitudinal disability changes.
interpretationCIDP is characterised by distinct serum inflammatory proteomic signatures comprising disease-specific and IG-responsive signatures. These candidate biomarkers may support improved patient stratification, disease monitoring, and prediction of treatment response, advancing individualised therapy in CIDP.
fundingErling-Persson Foundation, Sweden (#2022_0030 to ARP) and the German Research Foundation, Germany (KFO5023 TP8 to AM).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.